Antisense-Mediated Down-Regulation of Factor V-Short Splicing in a Liver Cell Line Model
Source abstract
Abstract
Coagulation factor V (FV) is a liver-derived protein encoded by the F5 gene. Alternative splicing of F5 exon 13 produces a low-abundance splicing isoform, known as FV-short, which binds the anticoagulant protein tissue factor pathway inhibitor (TFPIα) with high affinity, stabilising it in the circulation and potently enhancing its anticoagulant activity. Accordingly, rare F5 gene mutations that up-regulate FV-short splicing are associated with bleeding. In this study we have explored the possibility of decreasing FV-short splicing by antisense-based splicing modulation. To this end, we have designed morpholino antisense oligonucleotides (MAOs) targeting the FV-short-specific donor and acceptor splice sites and tested their efficacy in a liver cell line (HepG2) that naturally expresses full-length FV and FV-short. Cells were treated with 0–20 µM MAO, and full-length FV and FV-short mRNA expression was analysed by RT-(q)PCR. Both MAOs, alone or in combination, decreased the FV-short/full-length FV mRNA ratio down to ~50% of its original value in a specific and dose-dependent manner. This pilot study provides proof-of-principle for the possibility to decrease FV-short expression by antisense-mediated splicing modulation. In turn, this may form the basis for novel therapeutic approaches to bleeding disorders caused by FV-short over-expression and/or elevated TFPIα (activity) levels.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer-related gene regulation · RNA Research and Splicing · Hemophilia Treatment and Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 6200 MD Maastricht, The Netherlands
Funding
Dutch Thrombosis Foundation
References (44)
Show source-provided references
1. Splicing regulation: From a parts list of regulatory elements to an integrated splicing code10.1261/rna.876308 ↗
2. Alternative splicing: A pivotal step between eukaryotic transcription and translation10.1038/nrm3525 ↗
3. Expansion of the eukaryotic proteome by alternative splicing10.1038/nature08909 ↗
4. RNA splicing is a primary link between genetic variation and disease10.1126/science.aad9417 ↗
5. Splicing in the Diagnosis of Rare Disease: Advances and Challenges10.3389/fgene.2021.689892 ↗
6. Genetic therapies for RNA mis-splicing diseases10.1016/j.tig.2011.02.004 ↗
7. More than a messenger: Alternative splicing as a therapeutic target10.1016/j.bbagrm.2019.06.006 ↗
8. Balestra, D., and Branchini, A. (2019). Molecular Mechanisms and Determinants of Innovative Correction Approaches in Coagulation Factor Deficiencies. Int. J. Mol. Sci., 20.10.3390/ijms20123036 ↗
9. Splice-switching antisense oligonucleotides as therapeutic drugs10.1093/nar/gkw533 ↗
10. A deep intronic mutation in FGB creates a consensus exonic splicing enhancer motif that results in afibrinogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment10.1002/humu.20839 ↗
11. Antisense-based RNA therapy of factor V deficiency: In vitro and ex vivo rescue of a F5 deep-intronic splicing mutation10.1182/blood-2013-04-499657 ↗
12. Characterization of an apparently synonymous F5 mutation causing aberrant splicing and factor V deficiency10.1111/hae.12554 ↗
13. Regulation of a strong F9 cryptic 5′ss by intrinsic elements and by combination of tailored U1snRNAs with antisense oligonucleotides10.1093/hmg/ddv205 ↗
14. Treating Disease at the RNA Level with Oligonucleotides10.1056/NEJMra1705346 ↗
15. Antisense technology: A review10.1016/j.jbc.2021.100416 ↗
16. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders10.1111/ijlh.12508 ↗
17. A Bipartite Autoinhibitory Region within the B-domain Suppresses Function in Factor V10.1074/jbc.M112.377168 ↗
18. The role of phospholipids and factor Va in the prothrombinase complex10.1016/S0021-9258(19)86294-4 ↗
19. Biology of tissue factor pathway inhibitor10.1182/blood-2013-11-512764 ↗
20. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation10.1073/pnas.1310444110 ↗
21. The C-terminus of tissue factor pathway inhibitor-alpha inhibits factor V activation by protecting the Arg1545 cleavage site10.1111/jth.13559 ↗
22. Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα10.1172/JCI69091 ↗
23. Regulation of factor V and factor V-short by TFPIalpha: Relationship between B-domain proteolysis and binding10.1074/jbc.RA120.016341 ↗
24. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency10.1182/blood-2008-06-162453 ↗
25. Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIalpha) cofactors10.1002/rth2.12057 ↗
26. Dahlbäck, B., and Tran, S. (2021). The preAR2 region (1458–1492) in Factor V-Short is crucial for the synergistic TFPIalpha-cofactor activity with protein S and the assembly of a trimolecular Factor Xa-inhibitory complex comprising FV-Short, protein S and TFPIalpha. J. Thromb. Haemost., in press.10.1111/jth.15547 ↗
27. Characterization of a novel autosomal dominant bleeding disorder in a large kindred from east Texas10.1182/blood.V97.6.1549 ↗
28. A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function10.1182/blood-2014-08-592733 ↗
29. F5-Atlanta: A novel mutation in F5 associated with enhanced East Texas splicing and FV-short productio10.1111/jth.15314 ↗
30. Human Splicing Finder: An online bioinformatics tool to predict splicing signals10.1093/nar/gkp215 ↗
31. Morpholino antisense oligomers: Design, preparation, and properties10.1089/oli.1.1997.7.187 ↗
32. Hep G2 is a hepatoblastoma-derived cell line10.1016/j.humpath.2009.07.003 ↗
33. Haplotype-resolved and integrated genome analysis of the cancer cell line HepG210.1093/nar/gkz169 ↗
34. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification10.1093/nar/gnf056 ↗
35. Identification of a novel large deletion in a patient with severe factor V deficiency using an in-house F5 MLPA assay10.1111/hae.12536 ↗
36. Amplification efficiency: Linking baseline and bias in the analysis of quantitative PCR data10.1093/nar/gkp045 ↗
37. Anti-tissue factor pathway inhibitor (TFPI) therapy: A novel approach to the treatment of haemophilia10.1007/s12185-018-2548-6 ↗
38. Liver as a target for oligonucleotide therapeutics10.1016/j.jhep.2013.05.045 ↗
39. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers10.1016/j.coph.2005.07.001 ↗
40. F5-Atlanta: Factor V-short strikes again10.1111/jth.15351 ↗
41. Combinatorial regulation of alternative splicing10.1016/j.bbagrm.2019.06.003 ↗
42. Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients10.1111/hae.13679 ↗
43. Investigation of patients with unclassified bleeding disorder and abnormal thrombin generation for physiological coagulation inhibitors reveals multiple abnormalities and a subset of patients with increased tissue factor pathway inhibitor activity10.1111/ijlh.13155 ↗
44. Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency10.1182/bloodadvances.2020003464 ↗